Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

301. Use of point-of-care devices in patients with oral anticoagulation : a health technology assessment

Use of point-of-care devices in patients with oral anticoagulation : a health technology assessment Use of point-of-care devices in patients with oral anticoagulation : a Health Technology Assessment Use of point-of-care devices in patients with oral anticoagulation : a Health Technology Assessment Gailly J, Gerkens S, Van Den Bruel A, Devriese S, Obyn C,Cleemput I Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Gailly J, Gerkens S, Van Den Bruel A, Devriese S, Obyn C,Cleemput I. Use of point-of-care devices in patients with oral anticoagulation : a Health Technology Assessment. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 117C. 2009 Authors' conclusions Compared with laboratory INR testing, the testing of INR with point-of-care devices is a good option for patients with long term anticoagulation with vitamine K

Health Technology Assessment (HTA) Database.2009

302. Combined leg compression and anticoagulants effective in preventing venous thromboembolism

Combined leg compression and anticoagulants effective in preventing venous thromboembolism PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Combined leg compression and anticoagulants effective in preventing venous thromboembolism Clinical question Compared with single modalities, how effective is intermittent pneumatic leg compression combined with pharmacological prophylaxis in preventing (...) venous thromboembolism (VTE) in high-risk patients? Bottom line Compared with compression alone, combined prophylactic modalities significantly decrease the incidence of VTE, ie, symptomatic pulmonary embolism (PE) and deep vein thrombosis (DVT). Compared with pharmacological prophylaxis alone, combined modalities significantly reduce the incidence of DVT but the effect on PE could not be determined because of the lack of events in the included studies. Anticoagulants used in the trials included

Cochrane PEARLS2009

303. Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes

Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes Maxwell CB, Holdford DA, Crouch MA, Patel DA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the cost-effectiveness of four anticoagulation regimens that were recommended for moderate-to-high-risk patients with non-ST-elevation acute coronary syndrome. Bivalirudin was the least costly anticoagulation therapy for early invasive treatment, and fondaparinux was preferred for patients undergoing

NHS Economic Evaluation Database.2009

304. The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study

The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study Jowett S, Bryan S, Poller L, van den Besselaar AM, van der Meer FJ (...) of oral anticoagulants. The authors concluded that the two computer-assisted dosing programs were equally clinically effective and were cost saving, compared with manual dosing, which indicated that they were cost-effective. The methods were good and the results were well reported and reliable. The conclusions appear to be appropriate. Type of economic evaluation Cost-effectiveness analysis Study objective The objective was to assess the cost-effectiveness of computer-assisted anticoagulant dosing

NHS Economic Evaluation Database.2009

305. Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation

Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation Article Text Therapeutics Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation Statistics from Altmetric.com No Altmetric data available for this article. Study design Design: individual

Evidence-Based Medicine (Requires free registration)2009

306. Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin

Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarinOral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarinOral vitamin K did not reduce bleeding in patients with excessive anticoagulation

Evidence-Based Medicine (Requires free registration)2009

307. Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy

Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy Tillman J CRD summary The author concluded that regional citrate anticoagulation was associated with increased haemofilter circuit survival (...) time and lower risk of bleeding, compared with systemic heparin anticoagulation in continuous renal replacement therapy for patients with acute renal failure. The reliability of this conclusion is unclear, given restrictions in the search strategy, and failure to minimise errors and bias in the review process. Authors' objectives To compare systemic heparin and regional citrate anticoagulation in continuous renal replacement therapy for patients with acute renal failure. Searching The Cochrane

DARE.2009

308. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin

Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA CRD summary The authors concluded that there was insufficient evidence to support the use of pharmacogenetics to guide warfarin therapy. There were (...) some limitations in the reporting of review methods, but overall the review was well conducted and the authors’ conclusions are likely to be reliable. Authors' objectives To evaluate the safety and efficacy of genotype-guided warfarin dosing before anticoagulation. Searching PubMed, EMBASE and International Pharmaceutical Abstracts were searched through January 2009. Details of the search strategy were reported as being available online. No language restrictions were applied. Ongoing clinical

DARE.2009

309. Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage: a systematic review

Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage: a systematic review Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage: a systematic review Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage: a systematic review Romualdi E, Micieli E, Ageno W, Squizzato A CRD summary The optimal management of oral anticoagulant therapy after intracranial bleeding secondary (...) to vitamin K antagonist use in patients with a mechanical heart valve was investigated. The authors concluded that restarting or stopping anticoagulant therapy for a few days appeared to be safe, but the quality of evidence was low. The review was generally well conducted and the authors' conclusions appear appropriate. Authors' objectives To investigate the optimal management of oral anticoagulant therapy after intracranial bleeding secondary to the use of vitamin K antagonists in patients

DARE.2009

310. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis

Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis Nematullah A, Alabousi A, Blanas N, Douketis JD, Sutherland SE CRD summary This generally well-conducted review found no apparent increase in risk of bleeding associated (...) and underwent an elective dental procedure were eligible if they compared continuance on the usual dose of warfarin with reduction or cessation of usual warfarin dose. Eligible studies had to assess at least one of arterial or venous thromboembolism or postoperative bleeding (major, minor or clinically significant non-major). All of the included studies assessed patients who underwent dental extractions (single or multiple teeth). Most patients required anticoagulation therapy for prosthetic heart valves

DARE.2009

311. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety

Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative (...) clinical-effectiveness and safety Ndegwa S, Moulton K, Argaez C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ndegwa S, Moulton K, Argaez C. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety . Ottawa: Canadian Agency

Health Technology Assessment (HTA) Database.2009

312. Guidelines for the Management of Anticoagulant and Antiplatelet Therapy in Patients Undergoing Endoscopic Procedures

Guidelines for the Management of Anticoagulant and Antiplatelet Therapy in Patients Undergoing Endoscopic Procedures

British Society of Gastroenterology2009

313. [Selfmonitored anticoagulant therapy]

[Selfmonitored anticoagulant therapy] Selvmonitoreret blodfortyndende behandling – en kommenteret udenlandsk medicinsk teknologivurdering [Selfmonitored anticoagulant therapy] Selvmonitoreret blodfortyndende behandling – en kommenteret udenlandsk medicinsk teknologivurdering [Selfmonitored anticoagulant therapy] Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). Selvmonitoreret blodfortyndende behandling – en kommenteret udenlandsk medicinsk teknologivurdering. [Selfmonitored anticoagulant therapy] Copenhagen: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). 2(1). 2009 Authors' conclusions This report is a Danish commented version of an British HTA. The British HTA compares

Health Technology Assessment (HTA) Database.2009

314. Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped

Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped Article Text Clinical prediction guide Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2009

315. Anticoagulation Treatment For Prevention Of Recurrent Thromboembolism In Patients With Cancer

Anticoagulation Treatment For Prevention Of Recurrent Thromboembolism In Patients With Cancer "Anticoagulation Treatment For Prevention Of Recurrent Thromboembolism " by Carissa Honeycutt < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mary Von, MS, PA-C Second Advisor Rob Rosenow PharmD, OD Third Advisor Annjanette Sommers MS, PA-C Rights . Abstract Background: A comparison (...) of Low-Molecular Weight Heparin (LMWH) and oral anticoagulants is necessary in order to find the most effective prophylaxis for venous thromboembolism (VTE) and pulmonary embolism (PE) in cancer patients. The hypercoagulability state of cancer patients poses several risk factors and makes treatment and the potential complications more difficult to manage than in patients without cancer. By using the most effective treatment for anticoagulation in cancer patients, health care professionals can help reduce the risk

Pacific University EBM Capstone Project2009

316. 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both

6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both Article Text Therapeutics 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both Statistics from Altmetric.com No Altmetric data

Evidence-Based Medicine (Requires free registration)2008

317. Review: oral anticoagulants plus aspirin reduce arterial thromboembolism more than oral anticoagulants alone but only in patients with mechanical heart valves

Review: oral anticoagulants plus aspirin reduce arterial thromboembolism more than oral anticoagulants alone but only in patients with mechanical heart valves Review: oral anticoagulants plus aspirin reduce arterial thromboembolism more than oral anticoagulants alone but only in patients with mechanical heart valves | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: oral anticoagulants plus aspirin reduce arterial thromboembolism more than oral anticoagulants alone but only in patients

Evidence-Based Nursing (Requires free registration)2008

318. Anticoagulation - warfarin.

Anticoagulation - warfarin. Anticoagulation - warfarin. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006226 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information systematically derived from original guidelines. New on NGC Guideline Summaries NGC:011081 2016 NGC

Singapore Ministry of Health2008

319. An abnormal D-dimer test result indicated that anticoagulant therapy should be continued

An abnormal D-dimer test result indicated that anticoagulant therapy should be continued An abnormal D-dimer test result indicated that anticoagulant therapy should be continued | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An abnormal D-dimer test result indicated that anticoagulant therapy should be continued Article Text Therapeutics An abnormal D-dimer test result indicated that anticoagulant therapy should be continued Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any

Evidence-Based Medicine (Requires free registration)2008

320. Genetic determinants of response to warfarin during initial anticoagulation.

Genetic determinants of response to warfarin during initial anticoagulation. BACKGROUND: Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to various warfarin doses, but the role of these variants during initial anticoagulation is not clear. METHODS: In 297 patients starting warfarin therapy, we assessed CYP2C9 genotypes

NEJM2008 Full Text: Link to full Text with Trip Pro